You are here

Home » Content

Non-Hodgkin lenfomalı hastalardan elde edilen periferik stem cell ve kemik iliği hücrelerinin natural supresör aktivitesi üzerine interleukin-2'nin etkisi

The Effect of Interleukin-2 on Natural Suppressor Activity of Bone Marrow and Peripheral Stem Cell Products from Patients with non-Hodgkin's Lymphoma

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1997

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The activity of natural suppressor (NS) cells of peripheral stem cell (PSC) and bone marrow (BM) products from 24 patients with non-Hodgkin's lymphoma (NHL) were examined both before and following 5 days co-incubation with IL-2. This study showed that in the PSC products prior to IL-2 incubation, NS activity had been higher than both normal peripheral blood leukocytes (PBL) and BM products (p<0.001). Following IL-2 activation, NS activity of PSC decreased (p<0.05) while BM products' NS activity increased (p<0.05) compared to culture in the absence of IL-2. NS activity levels were significantly different between PBL from normal donors and PSC from patients with NHL after culture with IL-2 (p<0.05). As these results show, NS activity is higher in PSC from NHL patients than that of controls and in the presence of suppressor cells, lymphocytes from the PSC products of NHL patients did not respond to IL-2 with an increase in proliferative capacity. [Journal of Turgut Özal Medical Center 1997;4(1):1-6]
Bookmark/Search this post with
Abstract (Original Language): 
Non-Hodgkin lenfomalı 24 hastadan elde edilen periferik stem cell (PSC) ve kemik iliği ürünlerinin natural supresör (NS) hücre aktivitesi, IL-2 ile kültürden önce ve 5 gün IL-2 ile birlikte kültür yapılarak incelendi. Bu çalışmaya göre PSC ürünleri IL-2 ile stimüle edilmeden önce normal periferik kan lökositleri (PBL) ve kemik iliği (BM) ürünlerinden daha yüksek NS hücre aktivitesi gösterdi (p<0.001). lnterleukin-2 aktivasyonundan sonra, aktivasyon öncesine göre, PSC ürünlerinin NS hücre aktivitesi azalırken (p<0.05) BM'unki arttı (p<0.05). IL-2 ile kültürden sonra, normal donörlerden elde edilen PBL ile NHL'lı hastalardan elde edilen PSC ürünlerinin NS aktivitesi arasında istatistiki bakımdan önemli fark vardı (p<0.05). Bu sonuçlar, NHL'lı hastalarda NS aktivitesinin normalden daha yüksek olduğunu ve supresör hücrelerin varlığında NHL'lı hastaların PSC lenfositlerinin IL-2'ye proliferatif cevap vermediğini göstermektedir. [Turgut Özal Tıp Merkezi Dergisi 1997;4(l):l-6]
FULL TEXT (PDF): 
PDF icon arastirmax-non-hodgkin-lenfomali-hastalardan-elde-edilen-periferik-stem-cell-kemik-iligi-hucrelerinin-natural-supresor-aktivitesi-uzerine-interleukin-2nin-etkisi.pdf
  • 1
1-6
  • Turkish

REFERENCES

References: 

1. Kessinger A, Vose JM, Bierman PJ, et al. Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients. J Hematother 1993; 2(3):361-2.
2. Langenmayer I, Weaver C, Buckner CD, et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15:241-6.
3. Joshi SS, Kessinger A, Mann SL, et al. Detection of malignant cells in histologically normal bone marrow using culture techniques. Bone Marrow Transplant 1987; 1(3):303-10.
4. Anderson KC, Dzik WH. Transfusion medicine in hematopoietic stem cell and solid organ transplantation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ,
Silberstein LE, eds. Hematology Basic Principles and
Practice. 2nd ed. Churchill Livingstone, USA 1995; 2074-87.
5. Lum LG, Ueda M. Immunodeficiency and the role of suppressor cells after human bone marrow transplantation. Clin Immunol Immunopathol 1992; 63:103-9.
6. Gottschalk LR, Bray RA, Kaizer H, et al. Two populations of CD56 (Leu-19)+ /CD16+ cells in bone marrow transplant recipients. Bone Marrow Transplant 1990; 5:259-64.
7. Talmadge JE, Reed EC, Kessinger A, et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17:101-9.
8. Smith KA. Interleukin-2: Inception, impact, and implications. Science 1988; 240:1169-76.
9. Minami Y, Kono T, Miyazaki T, et al. The IL-2 receptor complex. Its structure, function, and target genes. Annu Rev Immunol 1993; 11:245-67.
10. Mass RA, Dulles HFJ, Den Otter W. Interleukin-2 in cancer
treatment: Disappointing or (still) promising? A review. Cancer Immunol Immunother 1993; 36:141-8.
11. Neubauer MA, Benyunes MC, Thompson JA, et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13:311-6.
12. Beverly B, Kang SM, Leonardo MJ, et al. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int J Immunol
1991; 4:661-71.
13. Houghton AN. Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994; 180:1-4.
14. Eberl G, Kessler B, Eberl LP, et al. Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12. Eur J Immunol 1996;26:
2709-16.
15. Rodriguez R, Angulo I, Vinuela JE, et al. Inhibition of bone marrow-derived natural suppressor activity by glucocorticoids and its reversal by IFN-g or IL-2. Transplantation 1994; 58:511-7.
16. Mortari F, Singhal SK. Production of human bone marrow-derived suppressor factor. Effect on antibody synthesis and lectin-activated cell proliferation. J Immunol 1988;
141:3037-42.
17. Mortari F, Bains MA, Singhal S. Immunoregulatory activity of human bone marrow identification of suppressor cells
possesing OKM-1, SSEA-1, and HNK-1 antigens. J Immunol 1986; 137:1133-7.
18. Moore SC, Theus SA, Barnett JB, et al. Cytokine regulation of bone marrow natural suppressor cell activity in the suppression of lymphocyte function. Cell Immunol 1992;
141:398-408.
19. Schreiber KL, Forman J. Effects of bone marrow-derived natural suppressor activity on B cell responses to lipopolysaccharide. Transplantation 1993; 56:700-8.
20. Soderberg LS. Differential activities of rabbit bone marrow suppressor cells. Int Arch Allergy Appl Immunol 1984;
74:341-6.
Journal of Turgut Özal Medical Center 4(1):1997
5
Natural supresör aktivite üzerine interleukin-2'nin etkisi
ÎH. Özerol ve ark.
21. Krakauer T. A macrophage-derived factor that inhibits the production and action of interleukin 2. J Leuko Biol 1985;
38:429-39.
22. Wallis RS, Fujiwara H, Ellner JJ. Direct stimulation of monocyte release of interleukin-1 by mycobacterial protein antigens. J Immunol 1986; 136:193-6.
23. Maes LY, York JL, Soderberg LS. A soluble factor produced by bone marrow natural suppressor cells blacks interleukin-2 production and activity. Cell Immunol 1988; 116:35-43.
24. Sugiura K, Ikehara S, Inaba M, et al. Enrichment of murine bone marrow natural suppressor activity in the fraction of hematopoietic progenitors with interleukin 3 receptor-associated antigen.. Exp Hematol 1992; 20:256-63.
25. Schmidt PA, Wright MA, Matthews JP, et al. Mechanisms
of immune suppression in patients with head and neck
cancer
: presence of CD34+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res
1995; 1:95-103.
26. Angulo I, Rodriguez R, Garcia B, et al. Involvement of nitric oxide in bone marrow derived natural suppressor activity. Its dependence on IFN-g. J Immunol 1995; 155:15-26.
27. Langrehr JM, Hoffman RA. Nitric oxide: A new endogenous immunomodulator. Transplantation 1993;
55:1205-12.
28.
the responses to phytohemagglutinin in the patients of non-Hodgkin's lymphoma who were candidates for high dose chemotherapy, autologous bone marrow, or peripheral stem cell transplantation J Turgut Özal Medical Center 1996;
3(4): 306-10.
29. Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, et al. T-
cell subsets and suppressor cells in human bone marrow.
Blood 1992; 80:3242-50.
30. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplantation in Europa: Activity in 1994. Report from the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996;
17:137-48.
31. Korbling M, Juttner C, Henon P, et al. Autologous blood stem cell versus bone marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl 1): 144-8.
32. Goldman JM. Peripheral blood stem cells for allografting.
Blood 1995; 85: 1413-6.
33. Appelbaum FR, Buckner CD. Overview of the clinical relevance of autologous bone marrow transplantation. Clin
Haematol 1986; 15:1-18.
34. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high dose therapy for malignancies. Blood 1991; 77:211-213.
35. Benyunes M, Massumoto C, Higuchi. Interleukin-2 + lymp hokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia: A preliminary report. Bone Marrow Transplant 1993;12:159-63.
36. Klingemann HG. Introducing graft-versus-leukemia into autologous stem cell transplantation. J Hematother 1995;
4:261-7.
37. Arbour S, Toupin S, Belanger R, et al. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation. Bone Marrow Transplant 1996; 17:315-22.
38. Robertson MJ, Ritz J. Biology and clinical relevance of
human natural killer cells. Blood 1990; 76:2421-38.
39. Salup RR, Wittrut RH. Treatment of adenocarcinoma in the peritoneum of mice: Chemo-immunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease. Cancer Immunol Immunother
1986; 22:268-71.
40. Verbik DJ, Jackson JD, Pirruccello SJ, et al. Functional and phenotypic characterization of human peripheral blood stem cell harvests: A comparative analysis of cells from consecutive collections. Blood 1995; 85:1964-70.
41. Mills CD. Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase
pathway. J Immunol 1991; 146:2719-23.
42. Weiss A, Fitch FW. Macrophages suppress CTL generation in rat mixed leukocyte cultures. J Immunol 1977; 119:510¬6.
43. Oehler JR, Herberman RB, Campbell DA, et al. Inhibition
of rat mixed lymphocyte cultures by suppressor macrophages. Cell Immunol 1977; 29:238-50.
44. Hibbs JB, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138:550-65.
45. Wu MX, Daley JF, Rasmussen RA, et al. Monocytes are required to prime peripheral blood T cells to undergo
apoptosis. Proc Natl Acad Sci USA 1995; 92:1525-9.
46. Stevens SR, Shibaki A, Meunier L, et al. Suppressor T cell activating macrophages in ultraviolet irradiated human skin induce a novel, TGF-beta dependent form of T cell activation characterized by deficient IL-2r-alpha expression. J Immunol 1995; 155:5601-7.
47. Munn DH, Pressey J, Beall AC, et al. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages: A potential mechanism of antigen-specific peripheral lymphocyte deletion. J Immunol 1996;156:523-
32.

Thank you for copying data from http://www.arastirmax.com